On Demand Activities

Inflammatory Bowel Disease Management Through Tele-Health: Navigating the New Normal

1.5 hr(s) | CME , NCPD

Specialty: Gastroenterology , Inflammatory Bowel Disease , Chrohn's Disease , Ulcerative Colitis

Therapeutic Area(s): Gastroenterology

Release Date: March 31, 2021

Expiration Date: March 31, 2022

Location: Internet Activity Enduring

During the COVID-19 pandemic clinicians are quickly having to change their patient management strategies to help control conditions during an unparalleled time with a stressed healthcare system, social –distancing, and fear of infection for vulnerable populations. By learning how to use telemedicine correctly clinicians can help to keep their patients with inflammatory bowel disease (IBD) properly managed and safe from COVID-19 infection through virtual interventions.

Innovative Blood-Based Screening in Cancer Care State of the Science and Future Opportunities for Accelerating Cancer Diagnoses

0.50 hr(s) | CME , MOC , Other , ABIM , Nurse Practitioners , Physician Assistants

Specialty: Blood-based cancer

Therapeutic Area(s): Oncology , Respiratory Medicine

Release Date: March 18, 2021

Expiration Date: March 17, 2022

Location: Internet Activity Enduring

In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.

Rewriting the Rules for Early Cancer Screening: Case-Based Insight on Primary Care Principles for Using Blood-Based Screening Techniques

0.50 hr(s) | CME

Specialty: Cancer

Therapeutic Area(s): Oncology

Release Date: March 25, 2021

Expiration Date: March 24, 2022

Location: Internet Activity Enduring

In this case-based activity, experts in oncology and primary care examine how to best integrate future blood-based cancer screening tools into clinical practice in order to reduce cancer-related morbidity and mortality.

Teaming Up to Improve Liver Cancer Outcomes Through Locoregional and Systemic Therapeutic Strategies

1.00 hr(s) | CME

Specialty: Liver Cancer

Therapeutic Area(s): Oncology , Radiology

Release Date: July 22, 2020

Expiration Date: July 21, 2021

Location: Internet Activity Enduring

In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy and explores using PARP inhibitors in the urology clinic.

Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer: Rationale, Evidence, and Clinical Implications

1.00 hr(s) | CME

Specialty: PARP Inhibitors

Therapeutic Area(s): Oncology

Release Date: July 22, 2020

Expiration Date: July 21, 2021

Location: Internet Activity Enduring

In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy and explores using PARP inhibitors in the urology clinic.

Optimizing Precision Medicine in Gastric Cancer Care: Essential Guidance on Translating Scientific Advances with Novel HER2-Targeted Therapies and Other Agents into Current Clinical Practice

1.00 hr(s) | CME , MOC , ABIM

Specialty: Gastric Cancer

Therapeutic Area(s): Oncology

Release Date: July 21, 2020

Expiration Date: July 20, 2021

Location: Internet Activity Enduring

In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into sound, evidence-based management strategies to improve outcomes for patients with gastric cancer.

Optimizing Precision Medicine in Ovarian Cancer: Expert Insights on Clinical Implications of PARP Inhibitor Therapy and Companion Diagnostics

1.00 hr(s) | CME , MOC , ABIM

Specialty: Ovarian Cancer

Therapeutic Area(s): Oncology

Release Date: July 21, 2020

Expiration Date: July 20, 2021

Location: Internet Activity Enduring

The advent of PARP inhibitors and precise selection of patients using companion diagnostics have improved outcomes for patients with advanced ovarian cancer and provided new opportunities for oncologists to individualize care. In this activity, based on a recent live webcast, a panel of leading experts discuss the rationale behind the use of PARP inhibition in ovarian cancer and how these agents and their companion diagnostics can be used in clinical practice in a variety of settings. Using case vignettes, the experts address real-world applications of the latest research, including how to prevent and manage adverse events associated with the use of PARP inhibitors and determine which patients may benefit from enrollment in clinical trials testing these agents alone or in combination with other treatments.

1 2 3 12
Copy link
Powered by Social Snap